PremiumCompany AnnouncementsBeOne Medicines Advances BG-85738 Into First-in-Human RAS Cancer Trial1d agoONC
PremiumCompany AnnouncementsRegeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside1d agoREGN
PremiumCompany AnnouncementsDupixent’s Next Move: STYLE 1 Itch Study Wraps Up for Regeneron and Sanofi1d agoREGN
PremiumBlurbsAnalysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and BioMarin Pharmaceutical (BMRN)2d agoAXGNBMRN
PremiumBlurbsAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)3d agoBHVNCYTK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
PremiumRatingsBioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged3d agoBMRN
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged